August 12, 2021 (Newswire.com) –
Subsequent Degree Pressing Care (NLUC) continues to supply the newest in therapeutic choices for the therapy of COVID-19. After collaborating within the earliest analysis research of the Regeneron Monoclonal Antibody Infusion, the NLUC crew is now proud to supply this unimaginable therapy in a lot of their clinic places.
The Subsequent Degree Pressing Care well being suppliers are dedicated to offering the very best accessible medical care and companies for all of their sufferers. “We’re devoted to making sure that our neighborhood has entry to cutting-edge remedies such because the Regeneron Monoclonal Antibody Infusions,” mentioned Subsequent Degree Pressing Care founder and CEO Juliet Breeze, MD.
Based on Breeze, the inpatient mortality fee for COVID-19 constructive people drops dramatically after they obtain the sort of therapy. Nevertheless, this advance in medical know-how is at present solely accessible at choose hospitals and clinics throughout the nation.
“The rationale we’re housing the Regeneron Monoclonal Antibody Infusion program at NLUC is straightforward: We need to be sure that all of our sufferers have entry to this life-saving therapy,” added Subsequent Degree Pressing Care Chief Medical Officer, Robbyn Traylor, MD.
For anybody who has examined constructive for COVID-19 and is excited about scheduling a Regeneron Monoclonal Antibody Infusion at one of many Subsequent Degree Pressing Care’s 17 clinics throughout the larger Houston space, go to the NLUC web site.
Director of Enterprise Improvement & Advertising
Workplace: 281.201.0657 x 108 | Fax: 281.336.0764
Supply: Subsequent Degree Pressing Care